Confusion after surgery is a scary reality for many older adults. It can make it hard to understand what is happening or follow simple instructions. A new trial looked at how to prevent this in people over 65 having thoracoscopic lung surgery. The team compared two IV medicine plans given over seven days. One group received a mix of dexmedetomidine and sufentanil. The other group received only sufentanil. Both medicines are given through a pump that lets patients control their own dose. The main goal was to see if the mix helped reduce the rate of postoperative delirium. The results showed a clear difference in confusion rates. The group getting the combination had a much lower rate of confusion than the control group. This mix also led to fewer cases of high blood pressure. Other measures like pain levels, nausea, and how long the hospital stay lasted did not differ significantly between the two groups. The study involved 287 patients. While the findings are promising, they come from a single trial. More research is needed to confirm these results in other settings.
Dexmedetomidine plus sufentanil cuts postoperative delirium risk to 4.9% vs 15.28% with sufentanil aloneCombining two drugs cuts confusion after lung surgery for older adults
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This randomized controlled trial enrolled 287 elderly patients aged 65 years and older scheduled for thoracoscopic lung surgery. The intervention group received IV patient-controlled dexmedetomidine injections combined with sufentanil (3 μg×kg sufentanil and 3 μg×kg DEX), while the comparator group received IV patient-controlled sufentanil injections (3 μg×kg sufentanil). The primary outcome was the incidence of postoperative delirium (POD) over a 7-day follow-up period.
The main result showed a significantly lower incidence of POD in the dexmedetomidine-sufentanil group at 4.9% compared to 15.28% in the sufentanil-only group (p = 0.006). No significant differences were found for secondary outcomes including duration of POD, incidence of postoperative nausea and vomiting, postoperative hospitalization duration, or pain assessment.
Safety data indicated that the incidence of hypertension was significantly lower in the test group (p < 0.001). No differences were found for other adverse events. Serious adverse events, discontinuations, and tolerability were not reported.
Key limitations include the lack of reported funding or conflicts, and the absence of specified practice relevance. The study population was limited to elderly patients undergoing a specific surgical procedure. These findings suggest a potential role for dexmedetomidine-sufentanil combination in reducing delirium risk, but broader applicability requires further investigation.